Advanced Proteome Therapeutics Corporation (APTCF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | - USD | -100.0% |
| 2022 | 636.41 Thousand USD | -29.11% |
| 2021 | 897.7 Thousand USD | 4371.55% |
| 2020 | 20.07 Thousand USD | -87.98% |
| 2019 | 166.98 Thousand USD | -9.07% |
| 2018 | 183.63 Thousand USD | 1.99% |
| 2017 | 180.06 Thousand USD | 47.9% |
| 2016 | 121.74 Thousand USD | -83.3% |
| 2015 | 728.92 Thousand USD | -15.0% |
| 2014 | 857.54 Thousand USD | 285.65% |
| 2013 | 222.36 Thousand USD | 49.37% |
| 2012 | 148.86 Thousand USD | -62.14% |
| 2011 | 393.23 Thousand USD | -28.57% |
| 2010 | 550.55 Thousand USD | -64.42% |
| 2009 | 1.54 Million USD | -40.46% |
| 2008 | 2.59 Million USD | 60.78% |
| 2007 | 1.61 Million USD | 0.0% |
| 2006 | - USD | -100.0% |
| 2005 | 196.13 Thousand USD | -73.15% |
| 2004 | 730.58 Thousand USD | -12.64% |
| 2003 | 836.26 Thousand USD | -58.1% |
| 2002 | 1.99 Million USD | -63.37% |
| 2001 | 5.44 Million USD | -35.68% |
| 2000 | 8.47 Million USD | -28.8% |
| 1999 | 11.89 Million USD | -25.68% |
| 1998 | 16 Million USD | 210.79% |
| 1997 | 5.15 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | - USD | 0.0% |
| 2023 Q1 | 399.04 Thousand USD | -37.3% |
| 2023 Q2 | 326.09 Thousand USD | -18.28% |
| 2023 FY | - USD | -100.0% |
| 2023 Q3 | 62.75 Thousand USD | -80.76% |
| 2023 Q4 | - USD | -100.0% |
| 2022 FY | 636.41 Thousand USD | -29.11% |
| 2022 Q3 | 855.08 Thousand USD | 0.14% |
| 2022 Q4 | 636.41 Thousand USD | -25.57% |
| 2022 Q2 | 853.88 Thousand USD | 11.05% |
| 2022 Q1 | 768.92 Thousand USD | -14.35% |
| 2021 Q2 | 35.41 Thousand USD | 66.6% |
| 2021 Q4 | 897.7 Thousand USD | -8.8% |
| 2021 Q3 | 984.37 Thousand USD | 2679.46% |
| 2021 Q1 | 21.25 Thousand USD | 5.89% |
| 2021 FY | 897.7 Thousand USD | 4371.55% |
| 2020 Q3 | 78.25 Thousand USD | 138.21% |
| 2020 FY | 20.07 Thousand USD | -87.98% |
| 2020 Q1 | 57.01 Thousand USD | -65.86% |
| 2020 Q2 | 32.85 Thousand USD | -42.38% |
| 2020 Q4 | 20.07 Thousand USD | -74.34% |
| 2019 FY | 166.98 Thousand USD | -9.07% |
| 2019 Q1 | 212.94 Thousand USD | 15.96% |
| 2019 Q3 | 59.66 Thousand USD | -28.08% |
| 2019 Q4 | 166.98 Thousand USD | 179.89% |
| 2019 Q2 | 82.95 Thousand USD | -61.04% |
| 2018 Q4 | 183.63 Thousand USD | -54.16% |
| 2018 Q1 | 319.13 Thousand USD | 77.24% |
| 2018 Q3 | 400.57 Thousand USD | 395.58% |
| 2018 FY | 183.63 Thousand USD | 1.99% |
| 2018 Q2 | 80.82 Thousand USD | -74.67% |
| 2017 FY | 180.06 Thousand USD | 47.9% |
| 2017 Q3 | 114.63 Thousand USD | -1.11% |
| 2017 Q4 | 180.06 Thousand USD | 57.07% |
| 2017 Q2 | 115.91 Thousand USD | 3.86% |
| 2017 Q1 | 111.6 Thousand USD | -8.33% |
| 2016 Q2 | 326.93 Thousand USD | -38.0% |
| 2016 Q4 | 121.74 Thousand USD | -22.15% |
| 2016 FY | 121.74 Thousand USD | -83.3% |
| 2016 Q1 | 527.3 Thousand USD | -27.66% |
| 2016 Q3 | 156.38 Thousand USD | -52.17% |
| 2015 FY | 728.92 Thousand USD | -15.0% |
| 2015 Q1 | 894.07 Thousand USD | 4.26% |
| 2015 Q3 | 558.05 Thousand USD | -10.42% |
| 2015 Q4 | 728.92 Thousand USD | 30.62% |
| 2015 Q2 | 622.95 Thousand USD | -30.32% |
| 2014 Q1 | 269.71 Thousand USD | 21.29% |
| 2014 Q2 | 626.11 Thousand USD | 132.14% |
| 2014 Q3 | 761.84 Thousand USD | 21.68% |
| 2014 FY | 857.54 Thousand USD | 285.65% |
| 2014 Q4 | 857.54 Thousand USD | 12.56% |
| 2013 Q3 | 432.32 Thousand USD | 247.91% |
| 2013 Q4 | 222.36 Thousand USD | -48.57% |
| 2013 Q2 | 124.26 Thousand USD | -47.19% |
| 2013 FY | 222.36 Thousand USD | 49.37% |
| 2013 Q1 | 235.3 Thousand USD | 58.06% |
| 2012 FY | 148.86 Thousand USD | -62.14% |
| 2012 Q1 | 231.45 Thousand USD | -41.14% |
| 2012 Q2 | 133.47 Thousand USD | -42.33% |
| 2012 Q3 | 175.97 Thousand USD | 31.85% |
| 2012 Q4 | 148.86 Thousand USD | -15.41% |
| 2011 FY | 393.23 Thousand USD | -28.57% |
| 2011 Q4 | 393.23 Thousand USD | -35.79% |
| 2011 Q3 | 612.46 Thousand USD | -30.02% |
| 2011 Q2 | 875.16 Thousand USD | -23.26% |
| 2011 Q1 | 1.14 Million USD | 107.14% |
| 2010 Q3 | 755.05 Thousand USD | -23.9% |
| 2010 Q4 | 550.55 Thousand USD | -27.08% |
| 2010 FY | 550.55 Thousand USD | -64.42% |
| 2010 Q1 | 1.28 Million USD | -16.85% |
| 2010 Q2 | 992.24 Thousand USD | -22.88% |
| 2009 Q3 | 1.8 Million USD | -10.22% |
| 2009 Q2 | 2 Million USD | -12.44% |
| 2009 Q4 | 1.54 Million USD | -14.17% |
| 2009 Q1 | 2.29 Million USD | -11.75% |
| 2009 FY | 1.54 Million USD | -40.46% |
| 2008 Q3 | 2.89 Million USD | -9.74% |
| 2008 FY | 2.59 Million USD | 60.78% |
| 2008 Q1 | 3.59 Million USD | 122.42% |
| 2008 Q2 | 3.2 Million USD | -10.76% |
| 2008 Q4 | 2.59 Million USD | -10.26% |
| 2007 Q3 | 2.85 Million USD | -6.26% |
| 2007 Q1 | 3.14 Million USD | 0.0% |
| 2007 Q2 | 3.04 Million USD | -3.14% |
| 2007 Q4 | 1.61 Million USD | -43.34% |
| 2007 FY | 1.61 Million USD | 0.0% |
| 2006 FY | - USD | -100.0% |
| 2006 Q1 | 111.59 Thousand USD | -43.1% |
| 2006 Q2 | 365.25 Thousand USD | 227.3% |
| 2006 Q3 | 300.1 Thousand USD | -17.84% |
| 2006 Q4 | - USD | -100.0% |
| 2005 Q3 | 548.22 Thousand USD | 0.51% |
| 2005 FY | 196.13 Thousand USD | -73.15% |
| 2005 Q1 | 552.92 Thousand USD | -24.32% |
| 2005 Q4 | 196.13 Thousand USD | -64.22% |
| 2005 Q2 | 545.44 Thousand USD | -1.35% |
| 2004 FY | 730.58 Thousand USD | -12.64% |
| 2004 Q4 | 730.58 Thousand USD | 36.65% |
| 2004 Q3 | 534.65 Thousand USD | 4.36% |
| 2004 Q2 | 512.32 Thousand USD | -9.82% |
| 2004 Q1 | 568.13 Thousand USD | -32.06% |
| 2003 Q1 | 1.44 Million USD | -27.36% |
| 2003 FY | 836.26 Thousand USD | -58.1% |
| 2003 Q2 | 775.87 Thousand USD | -46.48% |
| 2003 Q3 | 649.75 Thousand USD | -16.25% |
| 2003 Q4 | 836.26 Thousand USD | 28.7% |
| 2002 Q4 | 1.99 Million USD | -26.11% |
| 2002 FY | 1.99 Million USD | -63.37% |
| 2002 Q1 | 4.25 Million USD | -21.97% |
| 2002 Q2 | 3.31 Million USD | -21.94% |
| 2002 Q3 | 2.7 Million USD | -18.61% |
| 2001 Q4 | 5.44 Million USD | -15.76% |
| 2001 FY | 5.44 Million USD | -35.68% |
| 2001 Q2 | 6.58 Million USD | -14.39% |
| 2001 Q1 | 7.69 Million USD | -9.15% |
| 2001 Q3 | 6.46 Million USD | -1.83% |
| 2000 Q2 | 10.23 Million USD | -5.93% |
| 2000 Q1 | 10.87 Million USD | -8.59% |
| 2000 Q3 | 9.52 Million USD | -6.94% |
| 2000 FY | 8.47 Million USD | -28.8% |
| 2000 Q4 | 8.47 Million USD | -11.02% |
| 1999 FY | 11.89 Million USD | -25.68% |
| 1999 Q1 | 16.06 Million USD | 0.37% |
| 1999 Q4 | 11.89 Million USD | -27.99% |
| 1999 Q2 | 16.41 Million USD | 2.16% |
| 1999 Q3 | 16.52 Million USD | 0.65% |
| 1998 Q3 | 5.51 Million USD | 19.94% |
| 1998 Q1 | 4.47 Million USD | 0.0% |
| 1998 FY | 16 Million USD | 210.79% |
| 1998 Q2 | 4.6 Million USD | 2.84% |
| 1998 Q4 | 16 Million USD | 190.1% |
| 1997 FY | 5.15 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | 100.0% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 100.0% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 100.0% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | 100.0% |
| Rebus Holdings, Inc. | 5000.00 USD | 100.0% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 100.0% |
| Qrons Inc. | 420.00 USD | 100.0% |
| Adynxx, Inc. | - USD | NaN% |
| Neon Bloom, Inc. | 770.64 Thousand USD | 100.0% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 100.0% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | 100.0% |
| Skye Bioscience, Inc. | 11.94 Million USD | 100.0% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 100.0% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 100.0% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | 100.0% |
| SQZ Biotechnologies Company | 107.18 Million USD | 100.0% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | 100.0% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | 100.0% |
| Mesoblast Limited | 667.9 Million USD | 100.0% |
| Marizyme, Inc. | 22.01 Million USD | 100.0% |
| Genus plc | 1.02 Billion USD | 100.0% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | 100.0% |
| Pharming Group N.V. | 462.85 Million USD | 100.0% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 100.0% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | 100.0% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | 100.0% |
| ContraFect Corporation | 20.67 Million USD | 100.0% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | 100.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | NaN% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | 100.0% |
| IMV Inc. | 31.33 Million USD | 100.0% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 100.0% |
| MultiCell Technologies, Inc. | 126.22 USD | 100.0% |
| ONE Bio Corp. | 70.08 Million USD | 100.0% |
| Accustem Sciences Inc. | 939.68 Thousand USD | 100.0% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 100.0% |
| Arno Therapeutics, Inc. | - USD | NaN% |
| EV Biologics, Inc. | 431.71 Thousand USD | 100.0% |
| Q BioMed Inc. | 3.51 Million USD | 100.0% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 100.0% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | 100.0% |
| Biomind Labs Inc. | 73.81 Thousand USD | 100.0% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 100.0% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 100.0% |
| TetraLogic Pharmaceuticals Corporation | - USD | NaN% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 100.0% |
| GlobeStar Therapeutics Corporation | - USD | NaN% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 100.0% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | 100.0% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 100.0% |
| GB Sciences, Inc. | 103.44 Thousand USD | 100.0% |
| Alpha Cognition Inc. | 2.45 Million USD | 100.0% |
| HST Global, Inc. | 1526.00 USD | 100.0% |
| CSL Limited | 38.02 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | 100.0% |
| Halberd Corporation | 10.13 Thousand USD | 100.0% |
| Enzolytics Inc. | 361.7 Million USD | 100.0% |
| Agentix Corp. | 261.39 Thousand USD | 100.0% |
| Resverlogix Corp. | 8.11 Million USD | 100.0% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 100.0% |
| MetaStat, Inc. | - USD | NaN% |
| argenx SE | 4.54 Billion USD | 100.0% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 100.0% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | 100.0% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | 100.0% |
| GeneThera, Inc. | - USD | NaN% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 100.0% |
| AVAX Technologies, Inc. | 7.37 Million USD | 100.0% |
| Zenith Capital Corp. | 7410.00 USD | 100.0% |
| Genscript Biotech Corporation | 3.38 Billion USD | 100.0% |
| Ember Therapeutics, Inc. | 184.00 USD | 100.0% |
| Anthera Pharmaceuticals, Inc. | - USD | NaN% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | 100.0% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | 100.0% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | 100.0% |
| Kadimastem Ltd | 2.3 Million USD | 100.0% |
| Helix BioMedix, Inc. | 3.02 Million USD | 100.0% |
| VitaSpring Biomedical Co. Ltd. | - USD | NaN% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 100.0% |
| BioStem Technologies, Inc. | 14.56 Million USD | 100.0% |
| Oncology Pharma Inc. | - USD | NaN% |
| Reve Technologies, Inc. | 57.09 Thousand USD | 100.0% |
| LadRx Corporation | 2.3 Million USD | 100.0% |
| Cell Source, Inc. | 195.17 Thousand USD | 100.0% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 100.0% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 100.0% |
| NovAccess Global Inc. | 62.24 Thousand USD | 100.0% |
| Affymax, Inc. | 7.44 Million USD | 100.0% |
| Itoco Inc. | 1.4 Million USD | 100.0% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | 100.0% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | 100.0% |
| Mobile Lads Corp. | 52.00 USD | 100.0% |
| CytoDyn Inc. | 11.13 Million USD | 100.0% |
| Claritas Pharmaceuticals, Inc. | - USD | NaN% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | 100.0% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | 100.0% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | 100.0% |
| SYBLEU INC | 330.46 Thousand USD | 100.0% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | 100.0% |
| International Stem Cell Corporation | 5.39 Million USD | 100.0% |
| Bioxytran, Inc. | 137.63 Thousand USD | 100.0% |
| GlobeImmune, Inc. | - USD | NaN% |
| Predictive Technology Group, Inc. | - USD | NaN% |
| ProText Mobility, Inc. | 15 Million USD | 100.0% |
| Cardax, Inc. | - USD | NaN% |
| VG Life Sciences Inc. | - USD | NaN% |
| Kaleido Biosciences, Inc. | - USD | NaN% |
| Advaxis, Inc. | 16.57 Million USD | 100.0% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | 100.0% |
| RenovaCare, Inc. | - USD | NaN% |
| Regnum Corp. | 864.67 Thousand USD | 100.0% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 100.0% |
| Neutra Corp. | 2851.00 USD | 100.0% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 100.0% |
| PureTech Health plc | 693.97 Million USD | 100.0% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 100.0% |
| IXICO plc | 15.84 Million USD | 100.0% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 100.0% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 100.0% |
| CSL Limited | 38.02 Billion USD | 100.0% |
| Cellectis S.A. | 333.99 Million USD | 100.0% |